TB-500: A Complete User’s Guide
Most people arrive at TB-500 through an injury that won’t quit—a nagging tendon, a shoulder that’s been off for six months—and they want a straight answer to one question: does it actually work? It’s a fair question, but it skips something important. The better first question is: what exactly is TB-500, and is it the same thing as Thymosin Beta-4? The answer shapes everything downstream—dosing, sourcing, how you interpret the research, and what you should realistically expect. So that’s where we start.
TB-500 Is Not Thymosin Beta-4 (Exactly)
This is the single most important distinction in the entire topic, and it’s the one suppliers most often blur.
Thymosin Beta-4 is the natural, full-length protein found in nearly every cell in the human body. It’s 43 amino acids, with a molecular weight of 4,921 Daltons, first isolated from calf thymus tissue in 1981 by Allan Goldstein at the NIH. The large majority of published, peer-reviewed research used this full molecule.
TB-500 is a synthetic peptide fragment built around the active LKKTETQ region—just 7 amino acids, molecular weight 889 Daltons. Most of what people actually buy from suppliers is this fragment. Clinical research on the fragment specifically is limited compared to the full protein.
Here’s where confusion enters the market: some suppliers sell the true 7-amino-acid LKKTETQ fragment, while others sell longer sequences closer to the full Thymosin Beta-4 but still label the vial “TB-500.” Industry labeling is inconsistent. That inconsistency is exactly why third-party testing and source quality aren’t optional extras here—they’re the difference between knowing what you’re injecting and guessing.
How It Works: The Actin System
A peptide is a short chain of amino acids—conventionally fewer than 50. What makes peptides therapeutically interesting isn’t their size but their specificity; they act as precise signaling molecules rather than broad systemic agents. Insulin, oxytocin, and growth hormone are all peptides. TB-500 works the same way: it binds G-actin with high specificity and triggers a cascade of effects centered on cell migration, tissue repair, and inflammation modulation.
To understand that, you need the actin system. Every cell has a cytoskeleton—internal scaffolding that gives the cell its shape and lets it move. The main building block of that scaffolding is actin. G-actin is the free monomer (loose bricks); F-actin is the polymerized filament (assembled wall). When a cell needs to migrate toward an injury site, it converts G-actin into F-actin to build new scaffolding in the direction of travel. Actin makes up as much as 10% of all cellular protein, and Thymosin Beta-4—and by extension TB-500—binds G-actin and keeps a ready pool available for rapid mobilization when the cell needs to move.
A construction-site analogy makes this concrete. G-actin is the bricks—raw material available everywhere but directionless without coordination. The cell’s machinery is the workers—ready and capable, but without coordination the walls go up slowly and in the wrong direction. TB-500 is the foreman—it binds G-actin and releases it to the right workers at the right time and place, so the walls go up faster, straighter, and exactly where the injury site needs them.
Six mechanisms driving tissue repair
- Cell migration — supplies the actin that lets cells extend leading edges and move efficiently to injury sites. This is the primary driver of TB-500’s healing effect.
- Angiogenesis — endothelial cells need actin to migrate and form new blood vessels; the LKKTETQ sequence specifically promotes new vascular networks in healing tissue.
- Anti-inflammatory action — reduces pro-inflammatory cytokines, suppresses NF-κB activation, and lowers oxidative stress markers. It modulates the inflammatory phase rather than blocking it outright.
- Anti-apoptotic action — activates the Akt survival pathway through integrin-linked kinase (ILK), helping damaged cells survive the repair process rather than dying prematurely.
- Anti-fibrotic action — reduces scar formation by modulating collagen organization and suppressing myofibroblast activation; downregulates ROCK1 in cardiac tissue specifically.
- Oligodendrogenesis — promotes differentiation of oligodendrocyte progenitor cells into myelin-producing cells. Important caveat: this was demonstrated with the full Thymosin Beta-4 protein, not the fragment.
TB-500 vs. BPC-157: two different jobs
These two peptides get mentioned together constantly, but they do different things. BPC-157 works through growth factor signaling and nitric oxide modulation; it works best injected near or at the injury, promoting local tissue proliferation. In the construction metaphor, it’s the on-site crew doing the actual building. TB-500 works through cytoskeletal regulation and actin-driven cell migration; it distributes systemically regardless of injection site, which makes it effective even when the injury is hard to target directly. It’s the logistics that move the crew to the job site and make BPC-157’s local work possible at scale. For chronic tendinopathy or major injury, the combination is measurably better than either alone—the foundation of what’s commonly called the Wolverine Stack.
Who TB-500 Is Actually For
Four candidate profiles cover most legitimate use:
The chronic soft-tissue athlete. A nagging tendon, impingement, or ligament issue that hasn’t resolved with structured conservative care over 3+ months. This is the core use case.
The post-surgical optimizer. Cleared for rehab and looking to accelerate the tissue remodeling phase. Always coordinate timing with the surgical team—don’t start without clearance.
The aging lifter. Accumulated wear from years of training, with multiple small injuries that individually don’t warrant surgery but collectively limit movement quality and training capacity.
The post-illness recovery profile. Recovering from significant illness or extended physical stress, where the systemic migration and anti-inflammatory effects have application beyond musculoskeletal repair.
Who should skip it
Some situations are hard contraindications: pregnancy and lactation, and active malignancy. People with active or recent cancer should not use it without documented oncology clearance—the theoretical angiogenic concern warrants caution regardless of newer research showing suppression in some cancer types. And WADA-tested athletes should not touch it: TB-500 is banned, the detection window runs 30–45 days, and a positive test carries a 2–4 year competition ban with no exceptions.
It’s also worth being honest about what TB-500 is not. It’s the wrong tool for direct fat loss, muscle building, or acute performance enhancement—those aren’t its mechanisms. Setting accurate expectations up front prevents both disappointment and misuse.
Dosing
One framing note before the numbers: these tiers come from practitioner experience and extrapolation from Thymosin Beta-4 trial data. No human clinical trial has established optimal dosing for the TB-500 fragment specifically. Treat this as a starting framework, not a validated clinical protocol.
The three-tier ladder
Tier 1 — General optimization. 500 mcg to 1 mg subcutaneous daily, maintaining a steady tissue-repair signal rather than pulse-and-clear. Cycle 8 weeks on, 4 weeks off.
Tier 2 — Active injury and recovery. 2 to 2.5 mg subcutaneous twice per week for 4–6 weeks (loading), then 2 mg once per week for 4–6 weeks (maintenance). Total cycle 8–12 weeks. This is the standard protocol for most injury and post-surgical applications.
Tier 3 — Severe or complex injury. 5 mg twice per week for the first 2 weeks, then 2.5 mg twice per week for 4 weeks, then 2 mg once per week for 4–6 weeks maintenance. Total cycle 10–12 weeks.
Matching the tier to the context
| Condition | Tier | Timing | Notes |
|---|---|---|---|
| General longevity / tissue resilience | Tier 1 daily | 8 on, 4 off; ~3 cycles/year | Maintenance, not treatment |
| Acute soft-tissue injury | Tier 2 loading → maintenance | Start 48–72 hrs post-injury | 4 weeks loading, then maintenance |
| Chronic tendinopathy | Full Tier 2 cycle | 8–12 weeks total | Pair with eccentric loading rehab |
| Post-surgical recovery | Tier 2 | Start 14–21 days post-op with clearance | Never start without physician sign-off |
| Pre-surgical conditioning | Tier 2 | Start 4–6 wks before; stop 7–10 days prior; restart 14–21 days post-op | Must disclose to surgical team |
What to Expect, and When
TB-500 isn’t a peptide you feel acutely. Cellular signaling begins within 48–72 hours of the first injection, but observable improvement depends entirely on the tissue type being repaired. Tendons are slow. Muscle is faster. Managing this expectation is what prevents people from quitting too early.
- 48–72 hours: Cellular signaling initiated, G-actin binding begins. No subjective change expected yet.
- 10–14 days: First window for improvement in acute muscle strains; inflammation and stiffness may begin to ease.
- 2–4 weeks: Chronic inflammation and joint stiffness—most users begin reporting meaningful subjective change here.
- 4–8 weeks: Tendon and ligament repair window. Tendons heal slowly even with optimal intervention; patience is required.
- 3–6 weeks: Post-surgical recovery improvement, depending on procedure complexity.
The Wolverine Stack: TB-500 + BPC-157
The standard protocol runs BPC-157 and TB-500 in a 1:1 ratio at 250–500 mcg of each, daily. This matches how combined vials are commercially formulated, keeps the total peptide load reasonable, and works for the majority of injury and recovery applications. Both peptides run 8–12 weeks concurrently—don’t stagger them during a standard injury cycle. For severe injuries, push to 500 mcg of each daily for the first 2–4 weeks.
Combined BPC-157 + TB-500 vials are available from quality suppliers and reduce per-dose cost versus buying separately—just verify third-party testing on any combined formulation.
Why Cycle a Peptide That Doesn’t Desensitize?
Unlike hormones or receptor-binding compounds, TB-500 doesn’t classically desensitize—there’s no clear evidence that receptors downregulate with continuous use. So the rationale for cycling is different here, and it rests on three practical reasons: long-term human safety data doesn’t extend beyond several months of continuous exposure; cost and injection burden are real factors over time; and cycling creates natural durability-assessment windows, letting you observe what holds during the off-period and make better decisions about the next cycle.
| Pattern | Schedule | Best for |
|---|---|---|
| 8 weeks on, 4 off | Repeat 2–3×/year as needed | General optimization, most soft-tissue injuries |
| 12 weeks on, 4 off | Extended proliferative signaling | More involved injuries or post-surgical recovery |
| Targeted short cycle | 4–6 weeks of Tier 2 dosing | A specific acute injury; return to baseline after resolution |
One reassuring point: the tissue that healed during a cycle does not unheal. Cell migration and angiogenesis already happened. What can return toward baseline over the off-cycle window is background inflammation—but only if the underlying driver hasn’t changed.
Reconstitution
TB-500 ships lyophilized (freeze-dried) for stability and must be reconstituted with bacteriostatic water, which contains 0.9% benzyl alcohol as a preservative. Never use plain sterile water for any peptide you plan to keep beyond a single use.
Standard reconstitution: a 5 mg vial plus 2 mL of bacteriostatic water yields 2,500 mcg/mL; a 10 mg vial plus 3 mL yields roughly 3,333 mcg/mL.
Procedure: Wipe the rubber stopper with an alcohol swab. Draw 2 mL of bacteriostatic water, insert the needle, and direct the water down the inner wall of the vial—never spray directly onto the powder. Swirl gently; never shake, because foam denatures peptides. The solution should turn clear and colorless within 30–60 seconds. Label the vial with the reconstitution date.
Volume reference — 5 mg vial / 2 mL bac water
| Dose | Volume | Insulin syringe units |
|---|---|---|
| 250 mcg | 0.1 mL | 10 units |
| 500 mcg | 0.2 mL | 20 units |
| 1 mg | 0.4 mL | 40 units |
| 2 mg | 0.8 mL | 80 units |
| 2.5 mg | 1.0 mL | 100 units |
Storage: Lyophilized powder is stable 24+ months refrigerated at 2–8°C. Reconstituted solution is stable about 30 days refrigerated. Never freeze reconstituted peptide, and store it away from light.
Injection Technique
TB-500 is subcutaneous only, and—unlike BPC-157—it distributes systemically from any subcutaneous site, so you don’t need to inject near the injury for it to work. That’s a real practical advantage. Preferred sites, in order: the abdomen (about two inches lateral to the navel), the outer thigh, and the back of the upper arm. Rotate sites every injection to prevent lipodystrophy and site sensitization.
Use a 29–31 gauge insulin syringe, injecting at 45–90° depending on subcutaneous fat depth; thinner individuals should use 45° to avoid going intramuscular. Inject slowly, over roughly 5 seconds—rapid injection increases the likelihood of site reactions—and let the solution reach room temperature before injecting.
What to Track
Start a subjective daily log two weeks before the cycle, so you have a stable pre-intervention baseline rather than a single data point. Rate each of these on a 1–10 scale, morning and evening for injury-specific markers: pain in the affected area, range of motion during warm-up, load tolerance during training, sleep quality, energy on waking, and general training capacity.
For an objective lab baseline, consider a metabolic panel (CMP, CBC, lipids, fasting glucose and insulin, HbA1c), inflammatory markers (hs-CRP is the most likely to show meaningful change, plus ferritin), and a hormonal panel (thyroid, sex hormones, vitamin D). Retest at 8–12 weeks after cycle start.
Stacking Beyond the Basics
- + BPC-157 (the Wolverine Stack): the canonical first-choice pairing—1:1 ratio at 250–500 mcg each daily, delivering more than either alone for chronic tendinopathy or significant injury.
- + GHK-Cu: adds collagen remodeling. Introduce 1–2 mg daily near the injury site after 4 weeks of the Wolverine Stack—the remodeling agent applied once the structure exists.
- + CJC-1295 and ipamorelin: growth hormone secretagogues as a hormonal backdrop—CJC-1295 100 mcg plus ipamorelin 200–300 mcg before bed, 5 nights/week. Most relevant for users over 40.
- + Thymosin Alpha-1: for post-illness recovery or post-surgical immune support, at 1.6 mg twice per week—addressing immune reconstitution alongside tissue repair.
The most common stacking mistake is starting three new peptides at once. Introduce compounds one at a time; otherwise, when something goes wrong, you can’t identify the cause.
Troubleshooting
“I don’t feel anything.” Check five things in order: your baseline may already be good (less room to improve); your dose may be too low (Tier 1 at 500 mcg daily is maintenance, not injury treatment); your duration may be too short (tissue repair takes 4–8 weeks); your source quality may be poor; or the underlying problem may be mechanical or structural rather than tissue damage—peptides can’t fix a structural issue.
Injection site reactions are the most commonly reported side effect. Minimize them with 31-gauge needles, slow injection, consistent site rotation, and room-temperature solution. Red flags that warrant medical attention: spreading redness, significant swelling, persistent pain beyond 24 hours, or fever.
Lightheadedness after injection: inject slowly, eat something beforehand, and sit for a few minutes afterward. This usually resolves within the first few injections and isn’t a reason to discontinue unless it persists or worsens.
Identifying counterfeit product: be suspicious of prices far below market, no third-party testing certificate, inconsistent labeling, no mention of the LKKTETQ sequence or molecular weight, or product sold as a pre-mixed liquid rather than lyophilized powder.
Discontinue immediately and seek medical attention for a severe injection site reaction, fever above 100.4°F, significant rash or hives, difficulty breathing, facial swelling, or any sudden unusual systemic symptoms.
Frequently Asked Questions
Is TB-500 legal? In the US it sits in a regulatory gray zone—not FDA-approved, but sold legally as a research chemical. Possession is not federally illegal. WADA prohibits it for competitive athletes, with a 2–4 year ban for a positive test.
Will it affect my hormones? No. TB-500 doesn’t bind androgen, estrogen, or progesterone receptors, doesn’t suppress testosterone, and doesn’t affect the HPG axis. It’s safe to run alongside TRT without protocol changes.
Can I take it orally? Standard TB-500 has very poor oral bioavailability. Sublingual and capsule formulations exist, but the evidence supporting them is weak. Subcutaneous injection is the only route with predictable, reliable effects.
Will TB-500 cause cancer? The theoretical concern comes from its angiogenic activity. Notably, a 2023 study found Thymosin Beta-4 actually suppressed lung cancer via JAK2/STAT3 pathway inhibition, so the relationship is more complex than a simple pro-tumor effect. For healthy users the concern remains theoretical; for active or recent cancer, avoid it without oncology clearance.
What does it cost? Research-grade 5 mg vials run roughly $50–90. A standard 8–12 week cycle costs about $250–600. Combined BPC-157 + TB-500 vials run $60–110 and reduce the per-dose cost.
What about hair growth claims? Animal studies show stimulation of hair follicle stem cells, but no human trial data exists and anecdotal reports are mixed. This use is entirely off-label and shouldn’t be a primary reason to use the compound.
The Future Outlook
The most active clinical programs are pursuing the full Thymosin Beta-4 protein, not the TB-500 fragment. RegeneRx is developing RGN-352 (injectable) and RGN-259 (an ophthalmic formulation with FDA orphan drug status for neurotrophic keratopathy), and a Phase II trial (NCT05984134) in China for acute myocardial infarction is ongoing with 90 patients enrolled.
On the next-generation front, Ac-SDKP—the N-terminal tetrapeptide of Thymosin Beta-4—has specific anti-fibrotic activity and meaningfully better oral bioavailability, and a 2025 study showed inhaled recombinant human Thymosin Beta-4 was effective in pulmonary fibrosis models. Other LKKTETQ-containing fragments with modified pharmacokinetics are in earlier development.
The near-term milestone most worth following: the FDA Pharmacy Compounding Advisory Committee is scheduled to evaluate whether TB-500 should be added to the 503A Bulks List for wound healing in July 2026. If added, it would allow licensed compounding pharmacies to legally prepare TB-500 for patient use under physician prescription—a significant shift in the US regulatory landscape for users and practitioners alike.
The Bottom Line
To recap what matters most: TB-500 is the synthetic LKKTETQ fragment, not the full Thymosin Beta-4 protein, and most of the research used the full protein—a distinction that shapes everything from dosing to interpreting results. Its actin-binding mechanism drives cell migration, angiogenesis, and anti-inflammatory, anti-apoptotic, and anti-fibrotic signaling—the foreman sending the right bricks to the right workers at the right time. Dosing follows three tiers matched to severity, the standard cycle is 8 weeks on and 4 off, and timelines run weeks to months depending on tissue type, with tendons slow regardless of intervention. The Wolverine Stack—TB-500 plus BPC-157 in a 1:1 ratio, phasing in GHK-Cu around week 5—consistently outperforms either peptide alone.
TB-500 is a tool. It works best when the fundamentals are already in place. Use it for the right reasons, with the right protocol, in the right combinations, track your results, and stay honest about what’s working and what isn’t. That’s how you get the most out of any tool in this space.